50 results on '"Weiss, K.H."'
Search Results
2. EPH174 Trends in Hospitalization of Patients with Wilson's Disease in Germany
3. Trientine tetrahydrochloride versus d-Penicillamine for the management of patients with Wilson Disease: results from the CHELATE trial a year after randomisation
4. An Early Increase in Gamma Glutamyltranspeptidase And Low Aspartate Aminotransferase Peak Values Are Associated With Superior Outcomes After Orthotopic Liver Transplantation
5. Molekulare Diagnostik bei genetischen Lebererkrankungen
6. Hämochromatose und Morbus Wilson
7. Should kidney allografts from old donors be allocated only to old recipients?
8. PGI20 Prevelance and Treatment of Wilson Disease in Germany
9. Effect of mycophenolic acid on inosine monophosphate dehydrogenase (IMPDH) activity in liver transplant patients
10. Pringle Maneuver in Extended Liver Resection: Is it Justified?
11. Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase III study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial
12. The impact of individual extended donor criteria on short- and long-term outcome after liver transplant in the MELD-score era
13. Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions
14. Meta-analysis of the prognostic role of perioperative platelet count in posthepatectomy liver failure and mortality
15. Preoperative thrombocytopenia may predict poor surgical outcome after extended hepatectomy
16. Diagnose und Therapie des Morbus Wilson
17. Serological diagnosis of early HCC in NASH: A German multicenter study
18. Long term outcomes of treatment with Trientine in Wilson disease: Final results from a multicentre study in patients withdrawn from d-Penicillamine therapy
19. Long-term efficacy and safety of WTX101 in Wilson disease: Data from an ongoing extension of a phase 2 study (WTX101-201)
20. High caloric nutrition promotes hepatocellular damage and steatohepatitis in Wilson disease rats via amplified mitochondrial damage
21. Comment re: “Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping”
22. WTX101 in patients newly diagnosed with Wilson disease: final results of a global, prospective phase 2 trial
23. Soluble Axl identifies patients at higher risk for hepatocellular carcinoma development: results from a large scale multicenter analysis
24. Biliäre Komplikationen nach Lebertransplantation: Ergebnisse der endoskopischen und interventionellen Therapie
25. 832TiP - Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase III study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial
26. An Ongoing Phase 2, Multi-Centre, Open-Label, Study of WTX101 in Newly Diagnosed Wilson Disease Patients – Early Observations
27. Prospective Study to Assess Long-Term Outcomes of Treatment with Trientine in Wilson Disease Patients Withdrawn from Therapy with D-Penicillamine
28. LBA28 - Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions
29. SAT-047 - High caloric nutrition promotes hepatocellular damage and steatohepatitis in Wilson disease rats via amplified mitochondrial damage
30. FRI-138 - Serological diagnosis of early HCC in NASH: A German multicenter study
31. LBP-004 - Long term outcomes of treatment with Trientine in Wilson disease: Final results from a multicentre study in patients withdrawn from d-Penicillamine therapy
32. LBP-001 - Long-term efficacy and safety of WTX101 in Wilson disease: Data from an ongoing extension of a phase 2 study (WTX101-201)
33. P1313 : WTX101–201 : Phase 2 study of bis-choline tetrathiomolybdate in newly diagnosed wilson disease patients
34. P1310 : Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1) – a randomized, multidisciplinary, multinational phase III trial
35. THU-484 - Prospective Study to Assess Long-Term Outcomes of Treatment with Trientine in Wilson Disease Patients Withdrawn from Therapy with D-Penicillamine
36. PS020 - An Ongoing Phase 2, Multi-Centre, Open-Label, Study of WTX101 in Newly Diagnosed Wilson Disease Patients – Early Observations
37. 1391 PHENOTYPE–GENOTYPE CORRELATIONS IN SIBLINGS OF INDEX PATIENTS WITH WILSON DISEASE
38. 626 ELEVATED LEVELS OF VON WILLEBRAND FACTOR ARE ASSOCIATED WITH MAINTAINED NORMAL PRIMARY HAEMOSTASIS IN THROMBOCYTOPENIC PATIENTS WITH LIVER CIRRHOSIS
39. 1394 CONCOMITANT IMMUNE MEDIATED PHENOMENON IN WILSON DISEASE: IMPLICATION FOR MONITORING OF CHELATOR THERAPY
40. 1413 A FREQUENT PNPLA3 VARIANT PREDICTS DISEASE COURSE IN PRIMARY SCLEROSING CHOLANGITIS
41. 1 EFFICACY AND SAFETY OF D-PENICILLAMINE AND TRIENTINE FOR THE TREATMENT OF WILSON DISEASE
42. 1292 PSC ACTIVITY ASSESSMENT BY BILE PROTEOME ANALYSES AND CYTOLOGY
43. Heute rot, morgen tot? Die gastrointestinale Blutung im Spiegel der Notfallmedizin
44. 1113 SHIFTS OF THE BILIARY PROTEOMIC PATTERN IN PATIENTS WITH PSC DEPEND ON DISEASE ACTIVITY
45. 166 CONTRAST-ENHANCED CARDIAC MRI REVEALS PATHOLOGICAL MYOCARDIAL ALTERATIONS – CIRRHOTIC CARDIOMYOPATHY LINKED TO PORTAL HYPERTENSION
46. Hämochromatose und Morbus Wilson
47. 467 TYPE OF BILIARY INFECTION REDUCES SURVIVAL AFTER LIVER TRANSPLANTATION IN PATIENTS WITH BILIARY COMPLICATIONS
48. 664 PROTEOMIC ANALYSIS AND 2-D-GEL ELECTROPHORESIS OF BILE-DUCT BILE OF PRIMARY SCLEROSING CHOLANGITIS PATIENTS: A NEW DIAGNOSTIC APPROACH
49. Biliäre Komplikationen nach Lebertransplantation: Ergebnisse der endoskopischen und interventionellen Therapie
50. The α-sleep pattern: Results based on spectral and coherence analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.